128 related articles for article (PubMed ID: 38847660)
21. Emergent drug resistance with integrase strand transfer inhibitor-based regimens.
Lepik KJ; Harrigan PR; Yip B; Wang L; Robbins MA; Zhang WW; Toy J; Akagi L; Lima VD; Guillemi S; Montaner JSG; Barrios R
AIDS; 2017 Jun; 31(10):1425-1434. PubMed ID: 28375875
[TBL] [Abstract][Full Text] [Related]
22. Should We Be Testing for Baseline Integrase Resistance in Patients Newly Diagnosed With Human Immunodeficiency Virus?
Koullias Y; Sax PE; Fields NF; Walensky RP; Hyle EP
Clin Infect Dis; 2017 Oct; 65(8):1274-1281. PubMed ID: 28605418
[TBL] [Abstract][Full Text] [Related]
23. Virologic Failure Among People Living With HIV Initiating Dolutegravir-Based Versus Other Recommended Regimens in Real-World Clinical Care Settings.
Nance RM; Vannappagari V; Smith K; Johannes CB; Calingaert B; Saltus CW; Mayer KH; Whitney BM; Rodriguez B; Moore RD; Eron JJ; Geng E; Mathews WC; Mugavero MJ; Saag MS; Kitahata MM; Delaney JAC; Crane HM
J Acquir Immune Defic Syndr; 2019 Aug; 81(5):572-577. PubMed ID: 31107299
[TBL] [Abstract][Full Text] [Related]
24. Presence of V72I, G123S and R127K Integrase Inhibitor polymorphisms could reduce ART effectiveness: a retrospective longitudinal study.
Celotti A; Gargiulo F; Quiros-Roldan E; Properzi M; De Francesco MA; Coletto D; Caccuri F; Izzo I; Caruso A; Castelli F; Focà E
HIV Res Clin Pract; 2020 Feb; 21(1):24-33. PubMed ID: 32141388
[No Abstract] [Full Text] [Related]
25. Effectiveness of integrase strand transfer inhibitor-based regimens in HIV-infected treatment-naive individuals: results from a European multi-cohort study.
Rossetti B; Fabbiani M; Di Carlo D; Incardona F; Abecasis A; Gomes P; Geretti AM; Seguin-Devaux C; Garcia F; Kaiser R; Modica S; Shallvari A; Sönnerborg A; Zazzi M;
J Antimicrob Chemother; 2021 Aug; 76(9):2394-2399. PubMed ID: 34212176
[TBL] [Abstract][Full Text] [Related]
26. Associations of modern initial antiretroviral drug regimens with all-cause mortality in adults with HIV in Europe and North America: a cohort study.
Trickey A; Zhang L; Gill MJ; Bonnet F; Burkholder G; Castagna A; Cavassini M; Cichon P; Crane H; Domingo P; Grabar S; Guest J; Obel N; Psichogiou M; Rava M; Reiss P; Rentsch CT; Riera M; Schuettfort G; Silverberg MJ; Smith C; Stecher M; Sterling TR; Ingle SM; Sabin CA; Sterne JAC
Lancet HIV; 2022 Jun; 9(6):e404-e413. PubMed ID: 35659335
[TBL] [Abstract][Full Text] [Related]
27. Generally rare but occasionally severe weight gain after switching to an integrase inhibitor in virally suppressed AGEhIV cohort participants.
Verboeket SO; Boyd A; Wit FW; Verheij E; Schim van der Loeff MF; Kootstra N; van der Valk M; Reiss P;
PLoS One; 2021; 16(5):e0251205. PubMed ID: 33951089
[TBL] [Abstract][Full Text] [Related]
28. Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium.
Neesgaard B; Greenberg L; Miró JM; Grabmeier-Pfistershammer K; Wandeler G; Smith C; De Wit S; Wit F; Pelchen-Matthews A; Mussini C; Castagna A; Pradier C; d'Arminio Monforte A; Vehreschild JJ; Sönnerborg A; Anne AV; Carr A; Bansi-Matharu L; Lundgren JD; Garges H; Rogatto F; Zangerle R; Günthard HF; Rasmussen LD; Necsoi C; van der Valk M; Menozzi M; Muccini C; Peters L; Mocroft A; Ryom L
Lancet HIV; 2022 Jul; 9(7):e474-e485. PubMed ID: 35688166
[TBL] [Abstract][Full Text] [Related]
29. Antiretroviral Therapy Anchor-based Trends in Body Mass Index Following Treatment Initiation Among Military Personnel with HIV.
Kline MDA; Daniels C; Xu X; Sunil T; Ganesan A; Agan BK; Colombo RE; Kronmann KC; Blaylock JM; Okulicz JF; Markelz AE
Mil Med; 2021 Feb; 186(3-4):279-285. PubMed ID: 33128552
[TBL] [Abstract][Full Text] [Related]
30. Virologic outcomes among adults with HIV using integrase inhibitor-based antiretroviral therapy.
Lu H; Cole SR; Westreich D; Hudgens MG; Adimora AA; Althoff KN; Silverberg MJ; Buchacz K; Li J; Edwards JK; Rebeiro PF; Lima VD; Marconi VC; Sterling TR; Horberg MA; Gill MJ; Kitahata MM; Eron JJ; Moore RD;
AIDS; 2022 Feb; 36(2):277-286. PubMed ID: 34934020
[TBL] [Abstract][Full Text] [Related]
31. Immunological and virological efficacy of different antiretroviral regimens initiated during acute/recent HIV infection.
Ambrosioni J; Farrera J; de Lazzari E; Nicolás D; Manzardo C; Hernández-Meneses MM; Mosquera MM; Ligero C; Marcos MA; Sánchez-Palomino S; Fernández E; Plana M; Miró JM;
AIDS; 2020 Dec; 34(15):2269-2274. PubMed ID: 32910066
[TBL] [Abstract][Full Text] [Related]
32. Integrase Inhibitor-Based Antiretroviral Therapy Among Women Living with HIV: Data from the OPERA Cohort.
Fusco J; Henegar C; Quinlivan EB; Vannappagari V; Aboud M; Smith K; Fusco G
Curr HIV Res; 2019; 17(4):266-276. PubMed ID: 31560291
[TBL] [Abstract][Full Text] [Related]
33. Rapid ART start in early HIV infection: Time to viral load suppression and retention in care in a London cohort.
Girometti N; Lander F; McOwan A; Nwokolo N; Boffito M; Whitlock G;
HIV Med; 2020 Oct; 21(9):613-615. PubMed ID: 32869951
[TBL] [Abstract][Full Text] [Related]
34. Virological response to integrase strand transfer inhibitor-based antiretroviral combinations in HIV-1 group O-infected patients.
Alessandri-Gradt E; Unal G; Leoz M; Plantier JC;
AIDS; 2019 Jul; 33(8):1327-1333. PubMed ID: 30950879
[TBL] [Abstract][Full Text] [Related]
35. CD4/CD8 Ratio Recovery Among People Living With HIV Starting With First-Line Integrase Strand Transfer Inhibitors: A Prospective Regional Cohort Analysis.
Han WM; Avihingsanon A; Rajasuriar R; Tanuma J; Mundhe S; Lee MP; Choi JY; Pujari S; Chan YJ; Somia A; Zhang F; Kumarasamy N; Tek Ng O; Gani Y; Chaiwarith R; Pham TN; Do CD; Ditangco R; Kiertiburanakul S; Khol V; Ross J; Jiamsakul A;
J Acquir Immune Defic Syndr; 2023 Feb; 92(2):180-188. PubMed ID: 36625858
[TBL] [Abstract][Full Text] [Related]
36. Reduction of CD8 T Cell Functionality but Not Inhibitory Capacity by Integrase Inhibitors.
Richter E; Bornemann L; Korencak M; Alter G; Schuster M; Esser S; Boesecke C; Rockstroh J; Gunzer M; Streeck H
J Virol; 2022 Mar; 96(5):e0173021. PubMed ID: 35019724
[TBL] [Abstract][Full Text] [Related]
37. Integrase strand-transfer inhibitor use and cardiovascular events in adults with HIV: an emulation of target trials in the HIV-CAUSAL Collaboration and the Antiretroviral Therapy Cohort Collaboration.
Rein SM; Lodi S; Logan RW; Touloumi G; Antoniadou A; Wittkop L; Bonnet F; van Sighem A; van der Valk M; Reiss P; Klein MB; Young J; Jarrin I; d'Arminio Monforte A; Tavelli A; Meyer L; Tran L; Gill MJ; Lang R; Surial B; Haas AD; Justice AC; Rentsch CT; Phillips A; Sabin CA; Miro JM; Trickey A; Ingle SM; Sterne JAC; Hernán MA;
Lancet HIV; 2023 Nov; 10(11):e723-e732. PubMed ID: 37923486
[TBL] [Abstract][Full Text] [Related]
38. Predictors of Virological Failure and Time to Viral Suppression of First-Line Integrase Inhibitor-Based Antiretroviral Treatment.
Pyngottu A; Scherrer AU; Kouyos R; Huber M; Hirsch H; Perreau M; Yerly S; Calmy A; Cavassini M; Stöckle M; Furrer H; Vernazza P; Bernasconi E; Günthard HF;
Clin Infect Dis; 2021 Oct; 73(7):e2134-e2141. PubMed ID: 33095848
[TBL] [Abstract][Full Text] [Related]
39. Switch rates, time-to-switch, and switch patterns of antiretroviral therapy in people living with human immunodeficiency virus in Japan, in a hospital-claim database.
Ruzicka DJ; Kuroishi N; Oshima N; Sakuma R; Naito T
BMC Infect Dis; 2019 Jun; 19(1):505. PubMed ID: 31182050
[TBL] [Abstract][Full Text] [Related]
40. Impact of Integrase Inhibitors on Cardiovascular Disease Events in People With Human Immunodeficiency Virus Starting Antiretroviral Therapy.
Surial B; Chammartin F; Damas J; Calmy A; Haerry D; Stöckle M; Schmid P; Bernasconi E; Fux CA; Tarr PE; Günthard HF; Wandeler G; Rauch A;
Clin Infect Dis; 2023 Sep; 77(5):729-737. PubMed ID: 37157869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
